Scientists have harnessed CRISPR gene-editing technology to block the replication of the novel coronavirus in human cells — an approach that could one day serve as a new treatment for COVID-19.
However, the study was performed in lab dishes and has not yet been tested on animals or people, meaning a treatment based on the method could be years away.
CRISPR is a tool that enables researchers to precisely edit DNA. It’s based on a natural defense system used in bacteria that allows the microbes to target and destroy the genetic material of viruses, Live Science previously reported.
In the new study, published Tuesday (July 13) in the journal Nature Communications, the researchers used a CRISPR system that targets and destroys strands of RNA, rather than DNA. Specifically, their system uses an enzyme called Cas13b, which cleaves single strands of RNA, like those found in SARS-CoV-2, the virus that causes COVID-19. (Cas13b is similar to Cas9, the enzyme most commonly used in CRISPR gene-editing technology, but Cas9 cleaves DNA while Cas13b cleaves RNA.)
The researchers designed CRISPR-Cas13b to target specific sites on the RNA of SARS-CoV-2; once the enzyme binds to the RNA, it destroys the part of the virus needed to replicate, according to a statement from the Peter MacCallum Cancer Centre in Victoria, Australia, which collaborated on the research.
“Once the virus is recognized, the CRISPR enzyme is activated and chops up the virus,” study lead author Dr. Sharon Lewin, of the Peter Doherty Institute for Infection and Immunity at the University of Melbourne, told AFP.